Kymera Therapeutics (KYMR) Operating Expenses (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Operating Expenses data on file, last reported at $118.5 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 22.78% year-over-year to $118.5 million in Q1 2026; TTM through Mar 2026 was $410.6 million, a 21.8% increase from a year earlier, with the FY2025 full-year figure at $388.6 million, up 25.88% from the prior year.
• Operating Expenses for Q1 2026 stood at $118.5 million, up from $100.8 million in the prior quarter.
• Over the last five years, Operating Expenses for KYMR reached as high as $118.5 million in Q1 2026 and fell as low as $46.6 million in Q1 2022.
• Historically, Operating Expenses has averaged $74.6 million across 5 years, with a median of $68.1 million in 2024.
• On a YoY basis, Operating Expenses climbed as much as 46.07% in 2022 and fell as far as 11.15% in 2022.
• Year by year, Operating Expenses stood at $54.8 million in 2022, then rose by 22.69% to $67.2 million in 2023, then soared by 31.18% to $88.1 million in 2024, then increased by 14.31% to $100.8 million in 2025, then rose by 17.62% to $118.5 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $118.5 million in Q1 2026, $100.8 million in Q4 2025, and $95.3 million in Q3 2025.